With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG’s launch-tracking series will examine how the perception and performance of Zinbryta have evolved in the year since its launch in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profilesbut, on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.

What you will learn in this content:

  • What is U.S. neurologists’ awareness of and familiarity with Zinbryta, and what are their perceptions of the product?
  • To which patients are Zinbryta prescribers prescribing the drug, what are their reasons for prescribing it, and how satisfied are they with it?
  • What are the promotional messages and activities that Biogen and AbbVie are using to support the Zinbryta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How are the trial and adoption of Zinbryta tracking compared with other product launches in the MS market?

Methodology: ~75-100 U.S. neurologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten of these specialists participated in a 30-minute follow-up qualitative interview.

Key drugs: Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons

Key companies: Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche/Genentech

Related reports: Emerging Therapies: Ocrevus (Relapsing MS and PP-MS companion series), Emerging Therapies: Lemtrada

Table of contents

  • Zinbryta Launch Tracking Wave 3 (US)
    • Key Findings
    • Benchmarking Zinbryta's Launch Success vs. the Competition
      • Awareness of Zinbryta Has Improved, but the Drug Lags Behind Benchmark DMTs on Several Attributes at One Year Postlaunch
    • Prescriber and Nonprescriber Profiles
      • Differences Between Zinbryta Prescribers and Nonprescribers
    • Zinbryta Awareness and Perceptions
      • Unaided and Aided Awareness of Zinbryta
        • Unaided and Aided Awareness of Zinbryta Remains Behind Benchmark DMTs at One Year Postlaunch
      • Familiarity with Zinbryta
        • Awareness of Zinbryta's Attributes Remains Stable at One Year Postlaunch
      • Sources of Familiarity with Zinbryta
        • Academic Journals and Medical Meetings Help Drive Zinbryta Familiarity at One Year Postlaunch
      • Initial Reaction to and Interest in Zinbryta
        • Neurologists' Initial Reaction and Interest in Learning More About Zinbryta Waning at One Year Postlaunch
      • Impressions of Zinbryta
        • Neurologists' Concerns About Zinbryta's Side-Effect Profile Have Not Abated at One Year Postlaunch
      • Prescriber and Nonprescriber Profiles
        • Nonprescribers Remain Less Comfortable Managing Zinbryta Risks
    • Zinbryta Trial and Use
      • Willingness to Prescribe Zinbryta
        • Willingness to Prescribe Zinbryta Has Not Increased with Time
      • Number of Patients Currently Receiving Zinbryta
        • Use of Zinbryta May Be Shifting to Fourth or Later Lines of Therapy due to Physicians' Safety Concerns
      • Reasons for Not Yet Prescribing Zinbryta
        • Safety Concerns Continue to Hinder Zinbryta Prescribing at One Year Postlaunch
      • Anticipated Zinbryta Use
        • Zinbryta's Anticipated Patient Share Continues to Increase but Will Be Constrained by Ocrevus
      • Zinbryta Performance on Key Attributes
        • Prescribers Continue to Favorably Rate Zinbryta's Performance on Dosing Schedule and Efficacy
    • Effectiveness of Face-to-Face Detailing for Zinbryta
      • Frequency and Reach of Zinbryta Sales Representatives
        • At One Year Postlaunch, the Majority of Surveyed Neurologists Report Contact with a Zinbryta Representative Within the Past Three Months
      • Satisfaction with Zinbryta Sales Representative
        • Neurologists Continue to Be Satisfied with Zinbryta's Sales Representatives
      • Zinbryta Message Recall
        • Zinbryta Messaging at One Year Postlaunch Appears Focused on Efficacy and Risk
    • Methodology
      • Primary Market Research Methodology
    • Appendix

Author(s): Sarah Soucy

Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


Related Reports

Multiple Sclerosis | Access and Reimbursement | US | 2017`

The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (D...

View Details

Multiple Sclerosis | Access & Reimbursement | Detailed, Expanded Analysis (US)

The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMT

View Details

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will...

View Details

Multiple Sclerosis | Treatment Algorithms | Claims Data Analysis | US | 2018

With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the trea...

View Details